GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » Total Long-Term Liabilities

Stayble Therapeutics AB (STU:4K4) Total Long-Term Liabilities : €0.07 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Stayble Therapeutics AB Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Stayble Therapeutics AB's Total Long-Term Liabilities for the quarter that ended in Sep. 2023 was €0.07 Mil.

Stayble Therapeutics AB Total Long-Term Liabilities Historical Data

The historical data trend for Stayble Therapeutics AB's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB Total Long-Term Liabilities Chart

Stayble Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Long-Term Liabilities
Get a 7-Day Free Trial 0.08 0.13 0.10 0.08 0.08

Stayble Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.08 0.07 0.07

Stayble Therapeutics AB Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Stayble Therapeutics AB Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB (STU:4K4) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » Total Long-Term Liabilities
Comparable Companies
OSTO:ACTI XSAT:HAMLET B OSTO:SPRINT OSTO:ISOFOL OSTO:ABLI OSTO:ELIC OSTO:ALZ OSTO:BIOVIC B OSTO:NXTCL OSTO:BIOWKS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
STABL:Sweden 4K4:Germany
Address
Medicinaregatan 8a, Gothenburg, SWE, SE-413 90
Website
http://www.staybletherapeutics.com
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (STU:4K4) Headlines

No Headlines